









Markets
/
Stocks
/
nasdaq-aqst
/

Aquestive Therapeutics Inc

AQST

4.940USD

+0.110+2.28%

Close 09/18, 16:00（ET）Quotes delayed by 15 min

490.81MMarket Cap

LossP/E TTM



Aquestive Therapeutics Inc

4.940

+0.110+2.28%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-18

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a very weak stock market performance, the company shows strong technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

81 / 175

Overall Ranking

220 / 4721

Industry

Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 10 analysts

Buy

Current Rating

8.775

Target Price

+81.68%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Aquestive Therapeutics, Inc. is a pharmaceutical company. The Company is developing pharmaceutical products to deliver complex molecules through administrations that are alternatives to invasive and inconvenient standard of care therapies. It is advancing a product pipeline for the treatment of severe allergic reactions, including anaphylaxis. It has also developed a product pipeline focused on treating diseases of the central nervous system (CNS). Its PharmFilm technology is comprised of proprietary polymer compositions that serve as film formers to hold active pharmaceutical ingredients (APIs), and excipients in place. Its product portfolio and pipeline include Anaphylm, AQST-108, and Adrenaverse. Its CNS product candidate include Libervant. The Company’s Licensed commercial products and product candidates and other product includes Suboxone, Exservan, KYNMOBI, Zuplenz, Azstarys, Libervant, and Sympazan. Anaphylm is a non-device based, orally delivered epinephrine product candidate.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 20.72% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 57.56M.

Fairly Valued

The company’s latest PE is -7.12, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 54.90M shares, decreasing 4.48% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 4.33M shares of this stock.

Financial Health

Currency: USD Updated: 2025-09-18

The company's current financial score is 5.97, which is lower than the Pharmaceuticals industry's average of 7.84. Its financial status is stable, and its operating efficiency is low. Its latest quarterly revenue reached 10.00M, representing a year-over-year decrease of 50.23%, while its net profit experienced a year-over-year decrease of 393.55%.

Score

Industry at a Glance

Previous score

5.97

Change



Financials

6.07

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

6.93

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

4.22

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

5.49

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.11

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-18

The company’s current valuation score is 1.20, which is lower than the Pharmaceuticals industry's average of 2.06. Its current P/E ratio is -6.96, which is -40.30% below the recent high of -4.15 and -15.89% above the recent low of -8.06.

Score

Industry at a Glance

Previous score

1.20

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 81/175

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-18

The company’s current earnings forecast score is 8.40, which is higher than the Pharmaceuticals industry's average of 7.78. The average price target for Aquestive Therapeutics Inc is 8.50, with a high of 15.00 and a low of 4.75.

Score

Industry at a Glance

Previous score

8.40

Change

Support & Resistance

No Data

Analyst Rating

Based on 10 analysts

Buy

Current Rating

8.775

Target Price

+81.68%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

179

Total

Median

Average

Company name

Ratings

Analysts

Aquestive Therapeutics Inc

AQST

Biogen Inc

BIIB

Amgen Inc

AMGN

Alnylam Pharmaceuticals Inc

ALNY

Vertex Pharmaceuticals Inc

VRTX

Eli Lilly and Co

LLY

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-18

The company’s current price momentum score is 9.06, which is higher than the Pharmaceuticals industry's average of 6.64. Sideways: Currently, the stock price is trading between the resistance level at 5.71 and the support level at 3.84, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.06

Change

0.11

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(2)

Buy(3)

Indicators

Value

Direction

MACD(12,26,9)

0.042

Buy

RSI(14)

61.008

Neutral

STOCH(KDJ)(9,3,3)

28.228

Sell

ATR(14)

0.333

High Vlolatility

CCI(14)

25.092

Neutral

Williams %R

35.294

Buy

TRIX(12,20)

1.109

Sell

StochRSI(14)

23.354

Buy

Moving Average

Sell(2)

Neutral(0)

Buy(4)

Indicators

Value

Direction

MA5

4.966

Sell

MA10

5.007

Sell

MA20

4.501

Buy

MA50

4.212

Buy

MA100

3.627

Buy

MA200

3.389

Buy

Institutional Confidence

Currency: USD Updated: 2025-09-18

The company’s current institutional recognition score is 5.00, which is lower than the Pharmaceuticals industry's average of 6.26. The latest institutional shareholding proportion is 55.27%, representing a quarter-over-quarter increase of 0.86%. The largest institutional shareholder is The Vanguard, holding a total of 4.33M shares, representing 3.59% of shares outstanding, with 24.52% decrease in holdings.

Score

Industry at a Glance

Previous score

5.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Crestline Investors, Inc.

9.81M

BlackRock Institutional Trust Company, N.A.

5.44M

-1.43%

The Vanguard Group, Inc.

Star Investors

4.07M

-6.29%

Armistice Capital LLC

2.75M

Perceptive Advisors LLC

3.73M

Geode Capital Management, L.L.C.

1.70M

+2.79%

Barber (Daniel)

1.85M

+33.44%

Pale Fire Capital SE

1.34M

+154.05%

State Street Global Advisors (US)

1.52M

+1.25%

Risk Assessment

Currency: USD Updated: 2025-09-18

The company’s current risk assessment score is 3.16, which is lower than the Pharmaceuticals industry's average of 4.07. The company's beta value is 1.71. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.